A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

ONC201 (TIC10) is a first-in-class small molecule that inactivates the Ras effector target
kinases, Akt and ERK, selectively in tumor, but not normal, cells to safely trigger cancer
cell death. The dual inactivation of Akt and ERK by ONC201 results in broad-spectrum
cytotoxic activity that includes activation of TRAIL-mediated apoptotic and other downstream
antitumor effects to produce a potent antitumor response. The safety margin (ratio of
therapeutic dose to lowest dose with a mild adverse event) of ONC201 is at least 10-fold in
rats and dogs in GLP toxicology. The efficacy of ONC201 has been consistently demonstrated
in multiple in vitro, ex vivo, and in vivo preclinical cancer models. Favorable attributes
of ONC201 observed in preclinical models include antitumor efficacy with infrequent
administration, broad-spectrum activity independent of mutations or tumor type, orally
active, high safety margins, synergistic activity with many approved therapies, highly
stable, highly water soluble, and ability to penetrate the blood-brain barrier. In the phase
I portion of the trial, the hypothesis is that ONC201 will exhibit an acceptable safety
profile in patients with advanced cancer. In the phase II portion of the trial, the
hypothesis is that ONC201 will show preliminary signs of efficacy in patients with advanced
cancer as defined by endpoints that include progression-free survival, response rate,
biomarkers, and overall survival.

Inclusion Criteria:

1. Patients must have histologically confirmed glioblastoma multiforme, triple-negative
breast cancer, colorectal cancer, or non-small cell lung cancer patients with
advanced disease and limited therapeutic options.

2. Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. For
lymph nodes to be considered measurable, the short axis must be ≥15 mm when assessed
by CT scan. All other lesions (or sites of disease), including small lesions (longest
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are
considered non-measurable disease. Bone lesions, leptomeningeal disease, ascites,
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast
disease, and abdominal masses (not followed by CT or MRI), are considered
non-measurable. See Section 11 for the evaluation of measurable disease.

3. Patients are eligible for enrollment if they have not had prior chemotherapy,
radiotherapy, anticancer therapy, or investigational agent within 28 days prior to
the first dose (Week 1, Day 1); 42 days weeks in the case of alkylating agents.
Patients are eligible for enrollment if they have had no surgery within 6 weeks prior
to the first dose. Any number of prior therapies is allowable.

4. All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy,
and/or surgery) must be resolved, except for alopecia.

5. Age ≥18 years.

6. ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A).

7. Life expectancy of greater than 10 weeks.

8. Patients must have normal organ and marrow function as defined below:

- leukocytes ≥ 3,000/mcL

- absolute neutrophil count ≥ 1,500/mcL

- platelets ≥ 100,000/mcL

- hemoglobin > 8.0 mg/dL

- total bilirubin < 2.0 x upper limit of normal

- AST (SGOT)/ALT (SGPT) ≤2.5 × upper limit of normal creatinine OR creatinine
clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above normal.

9. The effects of ONC201 on the developing human fetus are unknown. For this reason,
women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while she or her partner is participating in this study, she should
inform her treating physician immediately.

10. Tumor specimen (paraffin-embedded block or frozen tissue) from prior resection or
biopsy available that is sufficient to perform pharmacodynamic assays (>3 slides for
IHC)

11. Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

1. Patients who have received bevacizumab therapy.

2. Patients with known brain metastases will be excluded from the phase I portion of the
study. In the phase II portion, patients with known CNS metastases will be limited to
20% of the patient population to accrue proportionately. Patients with CNS metastases
must be stable after therapy for CNS metastases (such as surgery, radiotherapy or
stereotactic radiosurgery) for > 3 month and must be off steroid treatment prior to
study enrollment and must have a life expectancy of 3 months or greater to be
eligible.

3. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ONC201 or its excipients.

4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements

5. Pregnant women are excluded from this study because ONC201 is novel agent with
unknown potential for teratogenic or abortifacient effects. Because there is an
unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with ONC201, breastfeeding should be discontinued if the
mother is treated with ONC201.

6. Patients with a known HIV-positive test on combination antiretroviral therapy are
ineligible for the initial first-in-man trial because of the potential for
pharmacokinetic interactions with ONC201. In addition, these patients are at
increased risk of lethal infections when treated with marrow-suppressive therapy.
Appropriate studies will be undertaken in patients receiving combination
antiretroviral therapy when indicated.

7. Patients with known history of cardiac arrhythmias including atrial fibrillation,
tachyarrhythmias or bradycardia will be excluded. Patients receiving therapeutic
agents known to prolong QT interval will be excluded. Patients with history of CHF,
or MI or stroke in the last 3 months will be excluded. Patients with a history of
seizures will be excluded form the initial trial because ONC201 crosses the
blood-brain barrier and this may affect their anti-seizure therapy.

8. Active drug use or alcoholism.